Cerebrospinal Fluid beta-Amyloid(1-42) Levels in the Differential Diagnosis of Alzheimer's Disease-Systematic Review and Meta-Analysis

Title
Cerebrospinal Fluid beta-Amyloid(1-42) Levels in the Differential Diagnosis of Alzheimer's Disease-Systematic Review and Meta-Analysis
Authors
김희진
Keywords
MILD COGNITIVE IMPAIRMENT; PHOSPHORYLATED-TAU; CSF BIOMARKERS; A-BETA-42/A-BETA-40 RATIO; ASSOCIATION WORKGROUPS; AMYLOID BETA(1-42); NATIONAL INSTITUTE; DEMENTIA; A-BETA-42; RECOMMENDATIONS
Issue Date
2015-02
Publisher
PUBLIC LIBRARY SCIENCE
Citation
PLOS ONE, v. 10, NO 2, Page. 1-16
Abstract
Objectives The purpose of this study was to carry out systematic review of the literature and metaanalysis to evaluate the diagnostic utility of cerebrospinal fluid (CSF) levels of the 42 amino acid form of amyloid-beta (A beta(1-42)) as a biomarker for differentiating Alzheimer's disease (AD) from non-AD dementia. Methods Design. Systematic literature review was used to evaluate the effectiveness of the A beta for the diagnosis of AD. The Scottish Intercollegiate Guidelines Network (SIGN) tool was used to evaluate independently the quality of the studies. Data sources. The literature review covered from January 1, 2004, to October 22, 2013, and searched eight domestic databases including Korea Med and international databases including Ovid-MEDLINE, EMBASE, and Cochrane Library. Data Extraction and Synthesis. Primary criteria for inclusion were valid studies on (i) patients with mild cognitive impairment with confirmed or suspected AD and non-AD dementia, and (ii) assessment of A beta(1-42) levels using appropriate comparative tests. Results A total of 17 diagnostic evaluation studies were identified in which levels of CSF A beta(1-42) were assessed. Meta-analysis was performed on 11 robust studies that compared confirmed AD (n = 2211) with healthy individuals (n = 1030), 10 studies that compared AD with non-AD dementias (n = 627), and 5 studies that compared amnestic mild cognitive impairment (n = 1133) with non-amnestic type subjects (n = 1276). Overall, the CSF A beta(1-42) levels were reduced in AD compared to controls or non-AD dementia. The effectiveness of test was evaluated for diagnostic accuracy (pooled sensitivity, 0.80 (95% CI 0.78-0.82)
URI
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0116802http://hdl.handle.net/20.500.11754/22122
ISSN
1932-6203
DOI
http://dx.doi.org/10.1371/journal.pone.0116802
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
Cerebrospinal Fluid β-Amyloid1–42 Levels in.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE